Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

$40m-$99.9m

SparingVision sees to new funding
Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.
V2Food dishes up $55m series B
Main Sequence Ventures, which co-founded the meat-free burger producer last year, has returned for a $55m series B round.
A2 coordinates $71.5m series B
UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.
Walden Biosciences welcomes $51m
Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.
XY spells out $59m series B
Zhejiang University-backed optical chip maker XY Technology will put the series B cash to strengthening its capacity and product.
Mosa Meat starts cooking up series B
Bell Food Group and M Ventures have contributed to an initial $55m series B tranche for the cultured meat developer spun out of Maastricht University.
Monte Rosa climbs $96m series B
University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.
Creative Biosciences designs $88m series C
Creative Biosciences has collected $88m in fresh funding, five years after being founded by a Sun Yat-Sen University professor.

Other News

Galecto gets $64m
A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.
Virogin Biotech transmits $62m series C
Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.
Corporates floor Lava with $83m
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.
Seegrid reframes latest round to $52m
CMU's warehouse vehicle manufacturer Seegrid has more than doubled its latest round to $52m, building on an initial $25m from G2VP six months ago.
Graphite Bio fleshes out $45m series A
Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.
Escape Bio hatches $73m
Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg

Login